# US 2021/0330709 A1 · Cell preparation for extemporaneous use, useful for healing and rejuvenation in vivo

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330709 A1
- Document ID: US20210330709A1
- Status: Published application
- Kind: A1
- Application number: 17/370,865
- Filed: 2021-07-08
- Published: 2021-10-28
- Earliest claimed: 2006-08-21
- Assignees: RegenLab USA LLC
- Applicants: RegenLab USA LLC
- Inventors: Antoine TURZI; Donald DU TOIT
- Web page: https://patentgrep.com/patent/US20210330709A1

## CPC

- A61K 35/19: Platelets; Megacaryocytes
- A61K 8/981: {of mammals or bird}
- A61K 8/983: {Blood, e.g. plasma}
- A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42)
- A61K 35/15: Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00)
- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61K 35/18: Erythrocytes (haemoglobin A61K38/42)
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61K 35/32: Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- A61K 35/35: Fat tissue; Adipocytes; Stromal cells; Connective tissues (adipose-derived stem cells A61K35/28; collagen A61K38/39)
- A61K 35/36: Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells (islets of Langerhans A61K35/39)
- A61K 35/38: Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A61K 38/363: {Fibrinogen}
- A61K 38/4833: {Thrombin (3.4.21.5)}
- A61L 24/0005: {Ingredients of undetermined constitution or reaction products thereof}
- A61L 24/106: {Fibrin; Fibrinogen}
- A61L 26/0042: {Fibrin; Fibrinogen}
- A61L 26/0057: {Ingredients of undetermined constitution or reaction products thereof}
- A61L 27/3691: {characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation}
- A61L 27/3886: {comprising two or more cell types}
- A61M 1/3693: {using separation based on different densities of components, e.g. centrifuging}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/08: Anti-ageing preparations
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K 2800/87: Application Devices; Containers; Packaging
- A61L 2430/02: for reconstruction of bones; weight-bearing implants
- A61M 2202/0427: Platelets; Thrombocytes
- C12Y 304/21005: Thrombin (3.4.21.5)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.

## Claims

### Claim at position 1

1-30. (canceled)

### Claim 31

A sterilized and sealed separator tube for preparing a cosmetic platelet concentrate from whole blood comprising:
an anticoagulant composition; and
a thixotropic gel;
wherein, when the separator tube is at least partially filled with the whole blood, and centrifuged once in a single centrifugation, blood components in the whole blood are separated into at least: (i) a supernatant comprising the cosmetic platelet concentrate; and (ii) red blood cells.

### Claim 32 (depends on 31)

The separator tube according to claim 31, wherein the cosmetic platelet concentrate contains greater than about 300 billion platelets per liter.

### Claim 33 (depends on 32)

The separator tube according to claim 32, wherein the cosmetic platelet concentrate contains greater than about 400 billion platelets per liter.

### Claim 34 (depends on 31)

The separator tube according to claim 31, further comprising an inlet adapted to introduce whole blood.

### Claim 35 (depends on 31)

The separator tube according to claim 31, wherein the separator tube is vacuum sealed.

### Claim 36 (depends on 34)

The separator tube according to claim 34, further comprising a needle.

### Claim 37 (depends on 31)

A method of making a cosmetic platelet concentrate comprising:
introducing whole blood from a subject to the separator tube of claim 31;
centrifuging the separator tube only once; and
separating the cosmetic platelet concentrate from the red blood cells after the first centrifugation.

### Claim 38 (depends on 37)

A cosmetic platelet concentrate prepared by the method of claim 37.

### Claim 39 (depends on 38)

A cosmetic composition comprising the cosmetic platelet concentrate according to claim 38, and at least one cosmetically acceptable excipient.

### Claim 40 (depends on 39)

The cosmetic composition according to claim 39, wherein the composition is in a form selected from the group consisting of a cream, emulsion, hydrogel, and combinations thereof.

### Claim 41 (depends on 39)

The cosmetic composition according to claim 39, wherein the cosmetic composition is a wrinkle filler composition.

### Claim 42 (depends on 31)

A method for promoting skin regeneration in a scar or wrinkle comprising:
introducing whole blood from a subject to the separator tube of claim 31;
separating the cosmetic platelet concentrate from the red blood cells after the first centrifugation, wherein separating optionally includes removing at least a portion of the supernatant;
optionally admixing the cosmetic platelet concentrate with at least one cosmetically acceptable excipient to prepare a skin care composition; and
applying the skin care composition to a scar or wrinkle.

### Claim 43 (depends on 42)

The method of claim 42, wherein applying the skin care composition to a scar or wrinkle comprises filling a wrinkle line with the skin care composition.

### Claim 44 (depends on 42)

The method of claim 42 wherein at least a portion of the supernatant is not removed when carrying out the separating process.

### Claim 45 (depends on 42)

The method according to claim 42, wherein applying the skin care composition to a scar or wrinkle comprises administering the skin care composition subcutaneously.

### Claim 46 (depends on 38)

The cosmetic platelet concentrate according to claim 38, comprising greater than about 300 billion platelets per liter.

### Claim 47 (depends on 46)

The cosmetic platelet concentrate according to claim 46, comprising greater than about 400 billion platelets per liter.

### Claim 48 (depends on 42)

The method according to claim 42, wherein the cosmetic platelet concentrate contains greater than about 300 billion platelets per liter.

### Claim 49 (depends on 48)

The method according to claim 48, wherein the cosmetic platelet concentrate contains greater than about 400 billion platelets per liter.

### Claim 50 (depends on 31)

The separator tube according to claim 31, wherein the separator tube has a useable vacuum of from 8 mL to 10 mL.

### Claim 51 (depends on 37)

The method according to claim 37, wherein the separator tube is centrifuged at about 3,800 revolutions per minute (rpm) for about 3.5 minutes.

### Claim 52 (depends on 31)

The separator tube according to claim 31, wherein the thixotropic gel is present in an amount of from about 1 mL to about 3 mL.

### Claim 53 (depends on 31)

The separator tube according to claim 31, wherein the anticoagulant is present in an amount of about 3.5 mg/mL.
